JP2017520613A5 - - Google Patents

Download PDF

Info

Publication number
JP2017520613A5
JP2017520613A5 JP2017503504A JP2017503504A JP2017520613A5 JP 2017520613 A5 JP2017520613 A5 JP 2017520613A5 JP 2017503504 A JP2017503504 A JP 2017503504A JP 2017503504 A JP2017503504 A JP 2017503504A JP 2017520613 A5 JP2017520613 A5 JP 2017520613A5
Authority
JP
Japan
Prior art keywords
oxy
compound
pharmaceutically acceptable
acceptable salt
tetrahydropyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017503504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520613A (ja
JP6625603B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/084607 external-priority patent/WO2016011931A1/en
Publication of JP2017520613A publication Critical patent/JP2017520613A/ja
Publication of JP2017520613A5 publication Critical patent/JP2017520613A5/ja
Application granted granted Critical
Publication of JP6625603B2 publication Critical patent/JP6625603B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017503504A 2014-07-22 2015-07-21 化合物 Active JP6625603B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/000695 2014-07-22
CN2014000695 2014-07-22
PCT/CN2015/084607 WO2016011931A1 (en) 2014-07-22 2015-07-21 Compounds

Publications (3)

Publication Number Publication Date
JP2017520613A JP2017520613A (ja) 2017-07-27
JP2017520613A5 true JP2017520613A5 (cg-RX-API-DMAC7.html) 2018-08-23
JP6625603B2 JP6625603B2 (ja) 2019-12-25

Family

ID=55162512

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017503504A Active JP6625603B2 (ja) 2014-07-22 2015-07-21 化合物
JP2017503553A Active JP6625604B2 (ja) 2014-07-22 2015-07-21 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017503553A Active JP6625604B2 (ja) 2014-07-22 2015-07-21 化合物

Country Status (14)

Country Link
US (5) US9783546B2 (cg-RX-API-DMAC7.html)
EP (2) EP3172211B1 (cg-RX-API-DMAC7.html)
JP (2) JP6625603B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170029516A (cg-RX-API-DMAC7.html)
CN (2) CN106536525B (cg-RX-API-DMAC7.html)
AR (1) AR101261A1 (cg-RX-API-DMAC7.html)
AU (2) AU2015292049B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016030939B1 (cg-RX-API-DMAC7.html)
CA (2) CA2970537C (cg-RX-API-DMAC7.html)
ES (2) ES2747636T3 (cg-RX-API-DMAC7.html)
RU (2) RU2690190C2 (cg-RX-API-DMAC7.html)
TW (1) TW201617348A (cg-RX-API-DMAC7.html)
UY (1) UY36224A (cg-RX-API-DMAC7.html)
WO (2) WO2016011931A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536525B (zh) * 2014-07-22 2019-05-03 葛兰素史密斯克莱知识产权发展有限公司 化合物
WO2017151939A1 (en) 2016-03-02 2017-09-08 The Brigham And Women's Hospital, Inc. Use of pla2g5-deficient suppressive macrophages in suppression of inflammation
US11583596B2 (en) * 2017-09-26 2023-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Radiolabeled Darapladib and analogs thereof and their use as imaging compounds
CN109988126B (zh) * 2017-12-29 2023-05-16 南京富润凯德生物医药有限公司 一种3-氨基-氧杂环丁烷衍生物及其制备方法和应用
CN109134523A (zh) * 2018-09-30 2019-01-04 中昊(大连)化工研究设计院有限公司 一种3,6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成新工艺
JP2022116370A (ja) * 2019-06-13 2022-08-10 アグロカネショウ株式会社 新規な1-ベンジルアミン誘導体及びこれを有効成分とする農園芸用薬剤
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
IL292668A (en) * 2019-11-09 2022-07-01 Shanghai Simr Biotechnology Co Ltd A tricyclic derivative of dihydroimidazopyrimidone, its preparation method, pharmaceutical preparation and its use
CN113666930B (zh) * 2020-05-13 2022-10-25 上海纽思克生物科技有限公司 桥环嘧啶酮类化合物、其制备方法、其组合物和用途
KR102842485B1 (ko) * 2020-05-13 2025-08-05 뉴스코 바이오테크 리미티드 가교 환상 피리미디논류 화합물, 그의 제조방법, 그의 조성물 및 사용
CN113861220B (zh) * 2020-06-30 2023-06-16 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
CN114057740B (zh) * 2021-12-15 2024-04-02 上海赛默罗生物科技有限公司 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途
KR20250055539A (ko) * 2022-08-04 2025-04-24 4비 테크놀로지스 (베이징) 컴퍼니 리미티드 Lp-pla2 억제제로서의 디하이드로이미다조-피리미디논 화합물 및 이의 용도
WO2024220459A2 (en) * 2023-04-18 2024-10-24 Scineuro Therapeutics Inc. Combination therapy with lp-pla2 inhibitor and a second agent
TWI896037B (zh) * 2023-07-17 2025-09-01 大陸商上海樞境生物科技有限公司 雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
WO2004014923A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
EP2619203A4 (en) * 2010-09-20 2014-04-16 Glaxo Group Ltd TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
JP2013545792A (ja) * 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
ES2773480T3 (es) * 2011-05-09 2020-07-13 Eip Pharma Llc Composiciones y métodos para tratar la enfermedad de Alzheimer
CA2843102A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Bicyclic pyrimidone compounds
JP2014521611A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド Lp−PLA2阻害剤としての2,3−ジヒドロイミダゾ[1,2−c]ピリミジン−5(1H)−オン化合物の使用
CN103827118B (zh) * 2011-07-27 2016-03-09 葛兰素集团有限公司 双环嘧啶酮化合物
EP2768517A4 (en) 2011-10-17 2015-03-11 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
JP6065786B2 (ja) 2012-09-14 2017-01-25 信越化学工業株式会社 化学増幅レジスト材料及びパターン形成方法
US20150344485A1 (en) * 2013-01-25 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
AU2014209949B2 (en) * 2013-01-25 2016-09-08 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol(1,2-c)pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (Lp-PLA2) inhibitors
CN103927116A (zh) * 2014-03-18 2014-07-16 兴唐通信科技有限公司 基于触屏设备的手势输入汉字的键盘和方法
CN106536525B (zh) * 2014-07-22 2019-05-03 葛兰素史密斯克莱知识产权发展有限公司 化合物

Similar Documents

Publication Publication Date Title
JP2017520613A5 (cg-RX-API-DMAC7.html)
RU2017105353A (ru) Соединения
JP2020510668A5 (cg-RX-API-DMAC7.html)
JP2019529514A5 (cg-RX-API-DMAC7.html)
JP2017528503A5 (cg-RX-API-DMAC7.html)
JP2017537066A5 (cg-RX-API-DMAC7.html)
JP2013519675A5 (cg-RX-API-DMAC7.html)
JP2016518337A5 (cg-RX-API-DMAC7.html)
JP2019524883A5 (cg-RX-API-DMAC7.html)
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
JP2017504635A5 (cg-RX-API-DMAC7.html)
FI3406609T3 (fi) Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
JP2014521735A5 (cg-RX-API-DMAC7.html)
JP2016505010A5 (cg-RX-API-DMAC7.html)
JP2013014622A5 (cg-RX-API-DMAC7.html)
JP2017513836A5 (cg-RX-API-DMAC7.html)
JP2013543896A5 (cg-RX-API-DMAC7.html)
JP2016510326A5 (cg-RX-API-DMAC7.html)
JP2016501221A5 (cg-RX-API-DMAC7.html)
JP2018521020A5 (cg-RX-API-DMAC7.html)
JP2017517538A5 (cg-RX-API-DMAC7.html)
JP2018530608A5 (cg-RX-API-DMAC7.html)
JP2019516739A5 (cg-RX-API-DMAC7.html)
JP2016522254A5 (cg-RX-API-DMAC7.html)
JP2010521516A5 (cg-RX-API-DMAC7.html)